Related Experiment Video
Updated: Jun 14, 2025
08:36
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
456
Myasthenia Gravis and COVID-19: A Systematic Review and Meta-analysis.
Amirhossein Nafari1, Seyedpouzhia Shojaei2, Reza Jalili Khoshnood3
1Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Basic and Clinical Neuroscience
|September 4, 2024
Summary
The pooled prevalence of COVID-19 infection in myasthenia gravis (MG) patients is 2%. This systematic review and meta-analysis analyzed 18 studies to determine COVID-19 infection rates in individuals with MG.
Area of Science:
- Neurology
- Infectious Diseases
- Autoimmune Disorders
Background:
- Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder.
- COVID-19 infection rates in MG patients vary across studies.
- Understanding COVID-19 prevalence in MG is crucial for patient management.
Purpose of the Study:
- To estimate the pooled prevalence of COVID-19 infection in individuals with myasthenia gravis.
- To synthesize existing research on COVID-19 in MG patients.
Main Methods:
- Systematic literature search of PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and gray literature up to October 2021.
- Inclusion of 18 articles after removing duplicates from an initial 253.
- Data extraction included participant numbers, MG patient counts, symptoms, hospitalization, and mortality.
Main Results:
- The pooled prevalence of COVID-19 infection among MG patients was 2% (95% CI, 1%-3%).
- Hospitalization prevalence among infected MG patients was 43% (95% CI, 26%-60%).
- MG exacerbation prevalence was 33% (95% CI, 20%-46%).
Conclusions:
- The pooled prevalence of COVID-19 infection in individuals with myasthenia gravis is 2%.
- A significant proportion of MG patients with COVID-19 experienced hospitalization and disease exacerbation.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:15Myasthenia Gravis: Diagnostic Tests
705
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
705
01:28Disorders of the Skeletal Muscle
905
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
905
01:26Chemical Synapses
8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.2K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.2K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K